Copyright © 2021. Inderes Oyj. All rights reserved.

CellaVision

Analyytikko

Sisäpiirin kaupat

Nettovaikuttavuus

Muut analyysit
20.7.
2022

Redeyes view on the Q2 report. With a powerful report and above our estimates, we adjust our forecasts for the rest of the current year. We increase our Base case to SEK 370 (340) and fair value range to SEK 230 – 520 (220 – 490) per share.

Muut analyysit
10.5.
2022

Redeyes view on the Q1 report. With a report slightly above our estimates, we only make minor adjustments to our forecasts for the current year. We leave our Base case at SEK 340 unchanged.

Muut analyysit
7.2.
2022

Redeyes view on the Q4 report. We make minor adjustments to our estimates for 2022, with a slightly lower growth assumption. We adjust our Base case to SEK 340 (330) per share with an unchanged fair value range.

Muut analyysit
4.2.
2022

Redeyes's first comments on the Q4 report earlier this morning.

Muut analyysit
22.10.
2021

Redeyes's first comments on the Q3 report earlier this morning.

Muut analyysit
20.7.
2021

Redeye views the Q2 from Cellavision this morning as very much in line with our expectations and continued solid recovery story.

Muut analyysit
28.4.
2021

Redeye’s first comments on CellaVision’s report for Q1’21. The report showed stronger sales than we expected at SEK 134m vs. our SEK 123m, a flat development compared to last year.

CellaVision